ComplianceOnline

FDA’s 2011 Draft Guidance on Financial Disclosure by Clinical Investigators – Overview of Recommendations

  • By: Staff Editor
  • Date: September 16, 2011
Webinar All Access Pass Subscription Abstract:

The FDA released draft guidance in May 2011 to assist clinical investigators, industry and FDA staff in interpreting and complying with regulations governing financial disclosures by clinical investigators, 21 CFR Part 54.

This article gives an overview of the recommendations included in the draft guidance. Comments on these draft guidelines were due by July 25, 2011.

Bookmark and Share

Compliance Trainings

Risk Based Monitoring for GCP Compliance
By - Laura Brown
On Demand Access Anytime

Compliance Standards

Best Sellers
You Recently Viewed
    Loading